These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27079)

  • 1. Mechanism for selectively inhibiting the activation of cyclic nucleotide phosphodiesterase and adenylate cyclase by antipsychotic agents.
    Weiss B; Levin RM
    Adv Cyclic Nucleotide Res; 1978; 9():285-303. PubMed ID: 27079
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective binding of antipsychotics and other psychoactive agents to the calcium-dependent activator of cyclic nucleotide phosphodiesterase.
    Levin RM; Weiss B
    J Pharmacol Exp Ther; 1979 Mar; 208(3):454-9. PubMed ID: 34709
    [No Abstract]   [Full Text] [Related]  

  • 3. An endogenous Ca2+-dependent activator protein of brain adenylate cyclase and cyclic neucleotide phosphodiesterase.
    Cheung WY; Lynch TJ; Wallace RW
    Adv Cyclic Nucleotide Res; 1978; 9():233-51. PubMed ID: 208377
    [No Abstract]   [Full Text] [Related]  

  • 4. [Psychotropic drugs and adenylate cyclase (author's transl)].
    Honda F
    Tanpakushitsu Kakusan Koso; 1977; 22(6):822-6. PubMed ID: 22102
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of calcium-dependent regulator-stimulated phosphodiesterase activity by neuroleptic drugs is unrelated to their clinical efficacy.
    Norman JA; Drummond AH; Moser P
    Mol Pharmacol; 1979 Nov; 16(3):1089-94. PubMed ID: 93689
    [No Abstract]   [Full Text] [Related]  

  • 6. Activation of adenylate cyclase by alcohols requires the nucleotide-binding protein.
    Luthin GR; Tabakoff B
    J Pharmacol Exp Ther; 1984 Mar; 228(3):579-87. PubMed ID: 6707909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase.
    Weiss B
    Adv Cyclic Nucleotide Res; 1975; 5():195-211. PubMed ID: 165666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do antipsychotic drugs work?
    Iversen LL
    Neurosci Res Program Bull; 1975 Aug; 13 Suppl():29-51. PubMed ID: 241033
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical evidence for multiple dopamine receptors in man.
    Meltzer HY
    Commun Psychopharmacol; 1979; 3(6):457-70. PubMed ID: 44694
    [No Abstract]   [Full Text] [Related]  

  • 10. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
    Onali P; Olianas MC; Gessa GL
    Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine-sensitive adenylate cyclase and dopamine/neuroleptic receptor binding: effect of neuroleptic drugs.
    Marshall AM; Mishra RK
    Adv Biochem Psychopharmacol; 1980; 24():153-7. PubMed ID: 6105772
    [No Abstract]   [Full Text] [Related]  

  • 12. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. M-1 and M-2 muscarinic receptor-mediated inhibition of dopamine-sensitive adenylate cyclase in rat neostriatum: a permissive role for D-2 dopamine receptors.
    Schoffelmeer AN; Hogenboom F; Mulder AH
    J Pharmacol Exp Ther; 1988 May; 245(2):658-63. PubMed ID: 2452877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of adrenal adenylate cyclase by guanine nucleotides. Promotion of nucleotide binding by calcium but not by adrenocorticotropic hormone.
    Mahaffee DD; Ontjes DA
    Mol Pharmacol; 1983 Mar; 23(2):369-77. PubMed ID: 6300646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro.
    Truss MC; Uckert S; Stief CG; Kuczyk M; Schulz-Knappe P; Forssmann WG; Jonas U
    Neurourol Urodyn; 1996; 15(1):59-70. PubMed ID: 8696357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual regulation of adenylate cyclase activity and hormone release in the intermediate lobe of the rat pituitary gland: evidence for the involvement of membrane components of the stimulatory beta 2-adrenergic system and of the inhibitory D-2 dopaminergic system.
    Cote TE; Frey EA; Sekura RD; Kebabian JW
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1985; 19():151-67. PubMed ID: 2988295
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanism of phenothiazine inhibition of Ca2+-dependent guanosine 3',5'-(cyclic) monophosphate phosphodiesterase of brain.
    Filburn CR; Colpo FT; Sacktor B
    Mol Pharmacol; 1979 Mar; 15(2):257-62. PubMed ID: 38390
    [No Abstract]   [Full Text] [Related]  

  • 18. Repartition and drug sensitivity of dopamine and L-isoproterenol-sensitive adenylate cyclases in rat brain homogenates.
    Prémont J; Tassin JP; Thierry AM; Bockaert J
    Adv Biochem Psychopharmacol; 1976; 15():347-56. PubMed ID: 192054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guanine nucleotide binding sites, responsible for adenylate cyclase activation and carbamylcholine binding inhibition, show similar properties in rat heart membranes.
    Waelbroeck M; Robberecht P; Chatelain P; Christophe J
    J Cyclic Nucleotide Res; 1981; 7(3):173-85. PubMed ID: 7287969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of calmodulin and dopaminergic activity in the striatum.
    Gnegy ME
    Fed Proc; 1982 May; 41(7):2273-7. PubMed ID: 6122610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.